Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Inhibition of Shedding of Low-Density Lipoprotein Receptor-Related Protein 1 Reverses Cartilage Matrix Degradation in Osteoarthritis.

Yamamoto K, Santamaria S, Botkjaer KA, Dudhia J, Troeberg L, Itoh Y, Murphy G, Nagase H.

Arthritis Rheumatol. 2017 Jun;69(6):1246-1256. doi: 10.1002/art.40080. Epub 2017 Apr 28.

2.

Development of a specific affinity-matured exosite inhibitor to MT1-MMP that efficiently inhibits tumor cell invasion in vitro and metastasis in vivo.

Botkjaer KA, Kwok HF, Terp MG, Karatt-Vellatt A, Santamaria S, McCafferty J, Andreasen PA, Itoh Y, Ditzel HJ, Murphy G.

Oncotarget. 2016 Mar 29;7(13):16773-92. doi: 10.18632/oncotarget.7780.

3.

Tissue-type plasminogen activator-binding RNA aptamers inhibiting low-density lipoprotein receptor family-mediated internalisation.

Bjerregaard N, Bøtkjær KA, Helsen N, Andreasen PA, Dupont DM.

Thromb Haemost. 2015 Jul;114(1):139-49. doi: 10.1160/TH14-08-0686. Epub 2015 Apr 9.

PMID:
25855589
4.

Protein-binding RNA aptamers affect molecular interactions distantly from their binding sites.

Dupont DM, Thuesen CK, Bøtkjær KA, Behrens MA, Dam K, Sørensen HP, Pedersen JS, Ploug M, Jensen JK, Andreasen PA.

PLoS One. 2015 Mar 20;10(3):e0119207. doi: 10.1371/journal.pone.0119207. eCollection 2015. Erratum in: PLoS One. 2015;10(4):e0126782.

5.

Development of a 'mouse and human cross-reactive' affinity-matured exosite inhibitory human antibody specific to TACE (ADAM17) for cancer immunotherapy.

Kwok HF, Botkjaer KA, Tape CJ, Huang Y, McCafferty J, Murphy G.

Protein Eng Des Sel. 2014 Jun;27(6):179-90. doi: 10.1093/protein/gzu010. Epub 2014 Apr 24.

PMID:
24769623
6.

Targeting tumor cell invasion and dissemination in vivo by an aptamer that inhibits urokinase-type plasminogen activator through a novel multifunctional mechanism.

Botkjaer KA, Deryugina EI, Dupont DM, Gårdsvoll H, Bekes EM, Thuesen CK, Chen Z, Ploug M, Quigley JP, Andreasen PA.

Mol Cancer Res. 2012 Dec;10(12):1532-43. doi: 10.1158/1541-7786.MCR-12-0349. Epub 2012 Oct 4. Erratum in: Mol Cancer Res. 2013 Aug;11(8):964. Chen, Zhou [corrected to Chen, Zhuo].

7.

Rezymogenation of active urokinase induced by an inhibitory antibody.

Jiang L, Botkjaer KA, Andersen LM, Yuan C, Andreasen PA, Huang M.

Biochem J. 2013 Jan 1;449(1):161-6. doi: 10.1042/BJ20121132.

PMID:
23016918
8.

Activation of pro-uPA is critical for initial escape from the primary tumor and hematogenous dissemination of human carcinoma cells.

Bekes EM, Deryugina EI, Kupriyanova TA, Zajac E, Botkjaer KA, Andreasen PA, Quigley JP.

Neoplasia. 2011 Sep;13(9):806-21.

9.

Nucleic acid aptamers against proteases.

Dupont DM, Andersen LM, Botkjaer KA, Andreasen PA.

Curr Med Chem. 2011;18(27):4139-51. Review.

PMID:
21838691
10.

Activation of the zymogen to urokinase-type plasminogen activator is associated with increased interdomain flexibility.

Behrens MA, Botkjaer KA, Goswami S, Oliveira CL, Jensen JK, Schar CR, Declerck PJ, Peterson CB, Andreasen PA, Pedersen JS.

J Mol Biol. 2011 Aug 12;411(2):417-29. doi: 10.1016/j.jmb.2011.05.026. Epub 2011 Jun 6.

PMID:
21669207
11.

Targeting the autolysis loop of urokinase-type plasminogen activator with conformation-specific monoclonal antibodies.

Botkjaer KA, Fogh S, Bekes EC, Chen Z, Blouse GE, Jensen JM, Mortensen KK, Huang M, Deryugina E, Quigley JP, Declerck PJ, Andreasen PA.

Biochem J. 2011 Aug 15;438(1):39-51. doi: 10.1042/BJ20110129.

12.

Comparative analysis of metastasis variants derived from human prostate carcinoma cells: roles in intravasation of VEGF-mediated angiogenesis and uPA-mediated invasion.

Conn EM, Botkjaer KA, Kupriyanova TA, Andreasen PA, Deryugina EI, Quigley JP.

Am J Pathol. 2009 Oct;175(4):1638-52. doi: 10.2353/ajpath.2009.090384. Epub 2009 Sep 3.

13.

Nonproteolytic induction of catalytic activity into the single-chain form of urokinase-type plasminogen activator by dipeptides.

Bøtkjaer KA, Byszuk AA, Andersen LM, Christensen A, Andreasen PA, Blouse GE.

Biochemistry. 2009 Oct 13;48(40):9606-17. doi: 10.1021/bi900510f.

PMID:
19705874
14.

A novel mode of intervention with serine protease activity: targeting zymogen activation.

Blouse GE, Bøtkjaer KA, Deryugina E, Byszuk AA, Jensen JM, Mortensen KK, Quigley JP, Andreasen PA.

J Biol Chem. 2009 Feb 13;284(7):4647-57. doi: 10.1074/jbc.M804922200. Epub 2008 Dec 1.

Supplemental Content

Loading ...
Support Center